Skip to Content

Filter by:

CMS Releases Coverage Decision for CAR T-Cell Therapy

August 8, 2019—The Centers for Medicare and Medicaid Services (CMS) Aug. 8 released the coverage decision for chimeric antigen receptor (CAR) T-cell therapy. Medicare will cover all Food and Drug Administration (FDA) approved uses for CAR T-cell therapy and off-label uses recommended by CMS-approved compendia.

Medicare will provide coverage for CAR T-cell therapy when administered at health care facilities enrolled in the FDA risk evaluation and mitigation strategies. Hospitals will not be required to participate in a clinical registry or study in order to receive reimbursement. Instead, CMS will use patient information collected by the FDA through post-market surveillance.


Mary Mullaney
Director, Hospital Payment Policies
Telephone: 202-909-2084

envelope on a green background

Subscribe to Washington Highlights

RSS icon

Subscribe to RSS

Washington Highlights, a weekly electronic newsletter, features brief updates on the latest legislative and regulatory activities affecting medical schools and teaching hospitals.

Past Issues

For More Information

Jason Kleinman
Senior Legislative Analyst, Govt. Relations
Telephone: 202-903-0806